CYTK Cytokinetics, Incorporated - Common Stock
NASDAQ · Biotechnology · Visualizza su SEC EDGAR ↗ chiudi Ott 2, 2026 10-K/10-Q Ago 6, 2026
$65,60
· % dell'intervallo 52 sett.
· sopra il minimo
· al massimo
$54,30minimo 52 sett.
$88,31massimo 52 sett.
Capitalizzazione di Mercato
$8.07B
P/E (TTM)
-9.1
EPS (TTM)
$-7.23
Ricavi (TTM)
$68M
i tuoi badge
Intervallo 52 sett.
$54–$88
Rating Analisti
BUY
Prezzo Obiettivo
$110
P/E
-9.1
ROE
329.8%
Margine di Profitto Netto
-1321.1%
La tua barra dei badge è vuota — aggiungi una metrica a piacere in questa pagina.
CYTK Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$65.60
Capitalizzazione di Mercato
$8.07B
P/E (TTM)
-9.1
EPS (TTM)
$-7.23
Ricavi (TTM)
$68M
ROE (TTM)
329.8%
D/E Debito/Patrimonio (MRQ)
-1.6
Intervallo 52 sett.
$54–$88
CYTK Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
intervallo
barre
La granularità delle barre si adatta al periodo selezionato — passa il mouse sul grafico per vedere apertura/massimo/minimo/chiusura di una barra.
Split azionari
| Data ex-dividendo | Split | Tipo |
|---|---|---|
| 25 Giugno 2013 | 1-for-6 | Inverso |
Informazioni su Cytokinetics, Incorporated - Common Stock Panoramica della società da Wikipedia
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
History
Cytokinetics was founded in 1997 by James Spudich, Ronald Vale, James Sabry and Lawrence S.B. Goldstein, four scientists at Stanford, UCSD, and UCSF. Operations began in 1998.
Initially, Cytokinetics focused on the possible pharmacological targets and areas of application of drugs based on cytoskeletal proteins. Eventually, the company narrowed its focus to the mechanics of muscle biology. Cytokinetics develops muscle activators and muscle inhibitors to improve muscle function in patients with cardiovascular and neuromuscular diseases.
In 2004 the company completed its initial public offering (IPO).
In January 2007, Cytokinetics named Robert I. Blum as president and CEO. Prior to this, Blum has been involved in the company since its founding, with roles in business development, corporate development and R&D.
In 2013, Cytokinetics finalized a licensing and discovery deal with Astellas to research treatment for muscle weakness and fatigue.
In July 2020, Ji Xing Pharmaceuticals signed a financing deal with Cytokinetics, which included the rights to commercialize the drug designed to treat hypertrophic cardiomyopathies, aficamten, in China and certain neighboring regions.
Products
Omecamtiv mecarbil is a cardiac muscle activator for the potential treatment of heart failure. In May 2020, omecamtiv mecarbil was granted fast track designation by the FDA for the treatment of chronic HF with reduced ejection fraction. Amgen purchased an option on omecamtiv mecarbil in 2006, and the two companies extended their partnership several times. In June 2013, Cytokinetics and Amgen expanded their licensing deal for omecamtiv mecarbil to include Japan. In November 2020 Amgen elected to terminate the collaboration, effective May 20, 2021, and Cytokinetics regained worldwide rights to develop and commercialize omecamtiv mecarbil.
Reldesemtiv (previously known as CK-2127107) is a next-generation fast skeletal muscle troponin activator (FSTA) that has undergone clinical trials for ALS.
Aficamten (previously known as CK-3773274) is an oral, small-molecule myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM).
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
settoreHealthcare
industriaBiotechnology
dipendenti673
paeseUS
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Ricavi$88M2016-12-31 → 2025-12-31
EPS$-6.542016-12-31 → 2025-12-31
Flusso di cassa libero$-535M2016-12-31 → 2025-12-31
Margine netto-1321.1%2016-12-31 → 2025-12-31
Valutazione e Rapporti
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
| Metrica | Tendenza 5 anni | CYTK | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| P/E (TTM) | -9.1media 5 anni ≈-12.2 | ≈-12.2 | · | · | |
| P/S | 91.6media 5 anni ≈323.5 | ≈323.5 | 41.9 | Sopravvalutato | |
| P/B | -12.2media 5 anni ≈-19.9 | ≈-19.9 | · | · | |
| EV / EBITDA | -13.7media 5 anni ≈-15.1 | ≈-15.1 | · | · | |
| Price / FCF (Prezzo / FCF) | -15.1media 5 anni ≈-16.6 | ≈-16.6 | · | · | |
| Price / Cash Flow (Prezzo / Flusso di cassa) | -15.8media 5 anni ≈-18.3 | ≈-18.3 | · | · | |
| EV / Revenue (EV / Ricavi) | 93.5media 5 anni ≈322.6 | ≈322.6 | · | · | |
| EV / FCF | -15.4media 5 anni ≈-16.6 | ≈-16.6 | · | · |
La mediana dei peer viene calcolata su base standardizzata per metrica e potrebbe non corrispondere sempre alla base TTM/MRQ mostrata per questo titolo.
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
| Metrica | Tendenza 5 anni | CYTK | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Margine Operativo (TTM) | -1046.1%media 5 anni ≈-2159.0% | ≈-2159.0% | -118.4% | Debole | |
| Margine EBITDA (TTM) | -1027.6%media 5 anni ≈-2113.0% | ≈-2113.0% | -118.4% | Debole | |
| Margine di Profitto Netto (TTM) | -1321.1%media 5 anni ≈-2357.7% | ≈-2357.7% | -176.2% | Debole | |
| ROA (TTM) | -56.8%media 5 anni ≈-47.8% | ≈-47.8% | -22.9% | Debole | |
| ROE (TTM) | 329.8%media 5 anni ≈322.1% | ≈322.1% | -13.2% | Di prim'ordine |
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
| Metrica | Tendenza 5 anni | CYTK | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Debito / Patrimonio Netto (MRQ) | -1.6media 5 anni ≈-0.4 | ≈-0.4 | 0.3 | Basso indebitamento | |
| Rapporto corrente (MRQ) | 6.7media 5 anni ≈6.7 | ≈6.7 | 5.9 | In linea | |
| Quick Ratio | 0.7media 5 anni ≈1.1 | ≈1.1 | 3.6 | Bassa liquidità | |
| Debito a lungo termine / Patrimonio netto (MRQ) | -1.4media 5 anni ≈-0.3 | ≈-0.3 | · | · | |
| Interest Coverage (Copertura degli interessi) | -13.4media 5 anni ≈-14.6 | ≈-14.6 | -7.7 | Bassa liquidità |
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
| Metrica | Tendenza 5 anni | CYTK | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Revenue YoY (Ricavi YoY) | 376.6%media 5 anni ≈98.1% | ≈98.1% | · | · | |
| Revenue CAGR 3Y (CAGR Ricavi 3Y) | -2.4%media 5 anni ≈-29.0% | ≈-29.0% | · | · | |
| Revenue CAGR 5Y (CAGR Ricavi 5Y) | 9.5% | · | · | · |
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
| Metrica | Tendenza 5 anni | CYTK | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Asset Turnover (Rotazione delle attività) | 0.1media 5 anni ≈0.1 | ≈0.1 | 0.2 | Debole | |
| Receivables Turnover (Rotazione dei crediti) | 5.1media 5 anni ≈4.8 | ≈4.8 | 5.7 | In linea | |
| Revenue / Employee (Ricavi / Dipendente) | ≈$130.8K | · | · | · |
valore · ≈ media 5 anni · mediana del settore · giudizio rispetto alla mediana
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
-4.4%
Prossimo report
Nov 03, 2026
| Periodo | Rapporto | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|---|
| 30 Giugno 2026 | Ago 5, 2026 | $-1.50 | $-1.67 | 10.4% |
| 31 Marzo 2026 | $-1.67 | $-1.69 | 0.94% | |
| 31 Dicembre 2025 | $-1.50 | $-1.49 | -0.97% | |
| 30 Settembre 2025 | $-2.55 | $-1.61 | -58.2% | |
| 30 Giugno 2025 | $-1.12 | $-1.41 | 20.3% | |
| 31 Marzo 2025 | $-1.39 | $-1.41 | 1.4% |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| R&D Expense | $416M | $339M | $330M | $241M | $160M | $97M | $86M | $89M | $90M | $60M | $46M | $44M | |
| SG&A Expense | $284M | $215M | $174M | $178M | $97M | $53M | $40M | $31M | $36M | $28M | $20M | $17M | |
| Operating Expenses | $700M | $555M | $504M | $419M | $257M | $150M | $126M | $120M | $127M | $88M | $66M | $62M | |
| Operating Income | $-612M | $-536M | $-496M | $-324M | $-186M | $-94M | $-99M | $-89M | $-113M | $19M | $-37M | $-15M | |
| Interest Expense | $46M | $38M | $28M | $19M | $16M | $16M | $7M | $4M | $3M | $3M | $268.0K | $0 | |
| Interest Income | · | · | · | $11M | $1M | $5M | $4M | $4M | · | $449.0K | $156.0K | $101.0K | |
| Other Non-op | $48M | $52M | $28M | $11M | $331.0K | $5M | $5M | $4M | $3M | $464.0K | $174.0K | $108.0K | |
| Pretax Income | · | · | · | · | · | · | · | $-106M | $-128M | $16M | $-38M | $-15M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| EPS (Basic) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.41 | $-0.97 | $-0.41 | |
| EPS (Diluted) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.39 | $-0.97 | $-0.41 | |
| Shares (Basic) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 39,943,000 | 38,814,000 | 35,709,000 | |
| Shares (Diluted) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 42,561,000 | 38,814,000 | 35,709,000 | |
| EBITDA | $-602M | $-527M | $-484M | $-318M | $-184M | $-92M | $-98M | $-88M | $-111M | $19M | $-37M | $-14M |
Stato Patrimoniale
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $123M | $95M | $113M | $66M | $113M | $83M | $36M | $42M | $125M | $67M | $65M | $20M | |
| Receivables | $18M | $17M | $1M | $147.0K | $52M | $4M | $5M | $2M | $1M | $24.0K | · | · | |
| Inventory | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $17M | $15M | $12M | $12M | $12M | $6M | $3M | $2M | $4M | $2M | $2M | $1M | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $1M | |
| Current Assets | $917M | $1.11B | $628M | $795M | $536M | $474M | $234M | $208M | $274M | $159M | $113M | $131M | |
| PP&E (Net) | $79M | $66M | $69M | $80M | $73M | $13M | $5M | $3M | $4M | $4M | $2M | $2M | |
| PP&E (Gross) | $126M | $103M | $97M | $98M | $89M | $38M | $29M | $27M | $26M | $25M | $23M | $22M | |
| Accum. Depreciation | $47M | $37M | $28M | $17M | $16M | $25M | $24M | $24M | $23M | $21M | $21M | $20M | |
| Other Non-current Assets | $17M | $8M | $8M | $10M | $7M | $6M | · | $300.0K | $429.0K | $200.0K | $200.0K | $200.0K | |
| Total Assets | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Accounts Payable | $22M | $20M | $22M | $26M | $21M | $8M | $8M | $4M | $5M | $4M | $2M | $1M | |
| Accrued Liabilities | $83M | $55M | $43M | $44M | $34M | $19M | $12M | $16M | $17M | $18M | $8M | $5M | |
| Current Liabilities | $202M | $180M | $103M | $85M | $72M | $31M | $26M | $22M | $32M | $33M | $32M | $24M | |
| Capital Leases | $108M | $113M | $120M | $127M | $112M | $440.0K | $2M | $771.0K | · | · | · | · | |
| Other Non-current Liabilities | · | $0 | $186.0K | $1M | $4M | $0 | · | $771.0K | $1M | $142.0K | · | · | |
| Total Liabilities | $2.08B | $1.54B | $1.21B | $1.12B | $597M | $420M | $301M | $185M | $185M | $76M | $47M | $41M | |
| Long-term Debt | $288M | $620M | $639M | $650M | · | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Total Debt | $288M | $105M | $68M | $64M | $47M | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Common Stock | $123.0K | $118.0K | $102.0K | $94.0K | $84.0K | $70.0K | $59.0K | $55.0K | $54.0K | $41.0K | $40.0K | $39.0K | |
| Paid-in Capital | · | · | · | · | $1.45B | · | · | · | · | · | · | $589M | |
| Retained Earnings | $-3.49B | $-2.70B | $-2.11B | $-1.59B | $-1.21B | $-992M | $-865M | $-743M | $-646M | $-518M | $-535M | $-497M | |
| AOCI | $630.0K | $2M | $-10.0K | $-4M | $-869.0K | $149.0K | $679.0K | $500.0K | $343.0K | $137.0K | $149.0K | $-4.0K | |
| Stockholders' Equity | $-660M | $-135M | $-386M | $-108M | $244M | $113M | $-11M | $26M | $110M | $94M | $69M | $92M | |
| Liabilities + Equity | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Shares Outstanding | 122,943,172 | 118,209,139 | 101,637,922 | 94,833,975 | 84,799,542 | 71,015,183 | 59,172,124 | 54,717,906 | 53,960,832 | 40,646,595 | 39,581,692 | 38,659,738 |
Flusso di cassa
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $10M | $10M | $12M | $6M | $2M | $2M | $1M | $1M | $2M | $741.0K | $589.0K | $490.0K | |
| Stock-based Comp | $112M | $98M | $72M | $48M | $27M | $18M | $11M | $10M | $9M | $7M | $5M | $3M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Other Non-cash | $153M | $86M | $28M | $36M | $44M | $117M | $19M | $-6M | $15M | $13M | $37M | $-34M | |
| Operating Cash Flow | $-510M | $-396M | $-414M | $-300M | $-143M | $9M | $-91M | $-101M | $-102M | $37M | $5M | $-45M | |
| CapEx | $25M | $4M | $1M | $11M | $49M | $11M | $3M | $889.0K | $3M | $2M | $562.0K | $1M | |
| Investing Cash Flow | $17M | $-553M | $239M | $-262M | $-148M | $-197M | $-75M | $5M | $-66M | · | · | · | |
| Net Debt Issued | $-11M | $-9M | · | $-48M | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Net Stock Activity | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Financing Cash Flow | $524M | $931M | $221M | $516M | $320M | $234M | $160M | $13M | $226M | · | · | · | |
| Net Change in Cash | $30M | $-18M | $46M | $-45M | $30M | $47M | $-6M | $-83M | $58M | $2M | $45M | $57.0K | |
| Taxes Paid | $0 | $0 | $0 | · | · | · | · | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | |
| Free Cash Flow | $-535M | $-400M | $-416M | $-311M | $-191M | $-2M | $-94M | $-102M | $-105M | $35M | $4M | $-46M | |
| Levered FCF | · | · | · | · | · | · | · | $-106M | $-108M | $33M | · | $-46M |
Redditività
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% | -168.3% | -368.0% | -282.3% | -848.3% | 17.6% | -130.5% | -31.4% | |
| Net Margin | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% | -228.0% | -452.9% | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| Pretax Margin | · | · | · | · | · | · | · | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| EBITDA Margin | -683.9% | -2851.1% | -6431.8% | -336.6% | -261.3% | -165.0% | -363.2% | -278.3% | -833.9% | 18.3% | -128.5% | -30.4% | |
| ROA | -55.5% | -53.0% | -57.2% | -41.9% | -31.3% | -30.9% | -48.6% | -42.0% | -55.0% | 11.5% | -30.2% | -13.6% | |
| ROE | 152.7% | 789.8% | 127.6% | 628.0% | -87.4% | -96.8% | 790.0% | -272.5% | -125.2% | 20.2% | -46.7% | -20.0% | |
| ROIC | · | · | · | · | · | · | · | -130.1% | -80.1% | 15.0% | -44.9% | -16.0% |
Liquidità e Solvibilità
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 | 15.2 | 9.0 | 9.4 | 8.5 | 4.8 | 3.6 | 5.5 | |
| Quick Ratio | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 | 2.8 | 1.6 | 2.0 | 3.9 | 2.0 | 2.1 | 0.8 | |
| Debt / Equity | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.6 | 0.3 | 0.3 | 0.2 | · | |
| LT Debt / Equity | -0.4 | -0.7 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.5 | 0.3 | 0.3 | 0.2 | · | |
| Interest Coverage | -13.4 | -14.2 | -17.5 | -16.7 | -11.3 | -5.9 | -14.9 | -23.4 | -37.6 | 6.9 | · | · |
Efficienza
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.7 | 0.2 | 0.4 | |
| Receivables Turnover | 5.1 | 2.1 | 10.5 | 3.6 | 2.5 | 11.7 | 7.3 | 18.8 | 23.5 | · | · | · |
Per Azione
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-5.37 | $-1.15 | $-3.80 | $-1.14 | $2.88 | $1.60 | $-0.18 | $0.47 | $2.04 | $2.32 | $1.73 | $2.38 | |
| Revenue / Share | $733.03 | $164.98 | $78.01 | $1053.03 | · | · | · | · | $0.27 | $2.50 | · | · | |
| Cash Flow / Share | $-4246.43 | $-3535.39 | $-4292.54 | $-3334.44 | · | · | · | · | $-2.06 | $0.87 | · | · | |
| Cash / Share | $1.00 | $0.80 | $1.11 | $0.69 | $1.33 | $1.17 | $0.62 | $0.77 | $2.32 | $1.65 | $1.64 | $0.52 | |
| EPS (TTM) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.39 | $-0.97 | $-0.41 |
Tassi di Crescita
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 376.6% | 145.3% | -92.0% | 34.3% | 26.2% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -2.4% | -36.0% | -48.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 9.5% | · | · | · | · | · | · | · | · | · | · | · |
Valutazione (TTM)
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| Net Income TTM | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| Market Cap | $7.81B | $5.56B | $8.49B | $4.35B | $3.87B | $1.48B | $628M | $346M | $440M | $494M | $414M | $310M | |
| Enterprise Value | $7.98B | $5.57B | $8.44B | $4.34B | $3.80B | $1.44B | $636M | $346M | $346M | $457M | $364M | · | |
| P/E | -9.7 | -8.9 | -15.3 | -10.6 | -16.3 | -10.5 | · | · | -3.1 | 31.2 | -10.8 | -19.5 | |
| P/S | 88.7 | 301.0 | 1126.9 | 45.9 | 54.9 | 26.4 | 23.4 | 11.0 | 32.9 | 4.6 | 14.4 | 6.6 | |
| P/B | -11.8 | -41.1 | -22.0 | -40.3 | 15.8 | 13.0 | -57.4 | 13.3 | 4.0 | 5.2 | 6.0 | 3.4 | |
| P / Tangible Book | · | · | · | · | 15.8 | 13.0 | · | · | · | · | · | · | |
| P / Cash Flow | -15.3 | -14.0 | -20.5 | -14.5 | -27.1 | 165.0 | -6.9 | -3.4 | -4.3 | 13.4 | 84.8 | -6.9 | |
| P / FCF | -14.6 | -13.9 | -20.4 | -14.0 | -20.2 | -699.7 | -6.7 | -3.4 | -4.2 | 14.0 | 95.8 | -6.7 | |
| EV / EBITDA | -13.2 | -10.6 | -17.4 | -13.6 | -20.6 | -15.6 | -6.5 | -3.9 | -3.1 | 23.5 | -9.9 | · | |
| EV / FCF | -14.9 | -13.9 | -20.3 | -14.0 | -19.9 | -682.3 | -6.8 | -3.4 | -3.3 | 12.9 | 84.1 | · | |
| EV / Revenue | 90.6 | 301.5 | 1121.0 | 45.9 | 54.0 | 25.8 | 23.7 | 11.0 | 25.9 | 4.3 | 12.7 | · | |
| Earnings Yield | -10.3% | -11.2% | -6.5% | -9.4% | -6.1% | -9.5% | · | · | -31.8% | 3.2% | -9.3% | -5.1% |
Conto Economico
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29M | $19M | $18M | $2M | $67M | $2M | $17M | $463.0K | $249.0K | $835.0K | $2M | $378.0K | $867.0K | $5M | $2M | $3M | |
| R&D Expense | $98M | $96M | $104M | $99M | $110M | $98M | $94M | $85M | $80M | $82M | $85M | $83M | $83M | $79M | $75M | $63M | |
| SG&A Expense | $104M | $105M | $92M | $69M | $66M | $57M | $62M | $57M | $51M | $46M | $44M | $40M | $40M | $50M | $54M | $48M | |
| Operating Expenses | $208M | $203M | $196M | $169M | $178M | $157M | $156M | $141M | $130M | $127M | $129M | $123M | $123M | $129M | $129M | $111M | |
| Operating Income | $-179M | $-184M | $-178M | $-167M | $-112M | $-156M | $-139M | $-141M | $-130M | $-126M | $-127M | $-122M | $-122M | $-124M | $-127M | $-108M | |
| Interest Expense | · | · | $14M | $11M | $11M | · | $9M | $9M | $13M | $7M | $7M | $7M | $7M | $7M | $7M | $7M | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $4M | |
| Other Non-op | $14M | $11M | $11M | $10M | $13M | $14M | $15M | $17M | $12M | $8M | $8M | $7M | $7M | $6M | $6M | $4M | |
| Net Income | $-199M | $-206M | $-183M | $-306M | $-134M | $-161M | $-150M | $-161M | $-143M | $-136M | $-137M | $-129M | $-129M | $-131M | $-137M | $-142M | |
| EPS (Basic) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| EPS (Diluted) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| Shares (Basic) | 132,086 | 123,273 | · | 119,982 | 119,457 | 118,496 | · | 117,685 | 109,240 | 101,924 | · | 96,071 | 95,755 | 95,164 | · | 93,758 | |
| Shares (Diluted) | 132,086 | 123,273 | · | 119,982 | 119,457 | 118,496 | · | 117,685 | 109,240 | 101,924 | · | 96,071 | 95,755 | 95,164 | · | 93,758 | |
| EBITDA | $-179M | $-180M | · | $-167M | $-112M | $-153M | · | $-141M | $-130M | $-124M | · | $-122M | $-122M | $-123M | · | $-108M |
Stato Patrimoniale
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $255M | $130M | $123M | $225M | $75M | $74M | $95M | $47M | $190M | $120M | · | $100M | $69M | $102M | · | $106M | |
| Receivables | $24M | $7M | $18M | $2M | $8M | $2M | $17M | $244.0K | $0 | $834.0K | · | $2M | $985.0K | $1M | · | $2M | |
| Inventory | $380.0K | $154.0K | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $18M | $14M | $17M | $13M | $20M | $16M | $15M | $7M | $11M | $19M | · | $20M | $20M | $16M | · | $14M | |
| Current Assets | $1.21B | $839M | $917M | $977M | $887M | $956M | $1.11B | $1.02B | $1.07B | $639M | · | $561M | $587M | $681M | · | $884M | |
| PP&E (Net) | $79M | $82M | $79M | $76M | $70M | $67M | $66M | $64M | $66M | $68M | · | $76M | $77M | $79M | · | $80M | |
| PP&E (Gross) | · | · | $126M | · | · | · | $103M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $47M | · | · | · | $37M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $19M | $18M | $17M | $17M | $15M | $13M | $8M | $8M | $8M | $8M | · | $8M | $8M | $8M | · | · | |
| Total Assets | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Accounts Payable | $21M | $25M | $22M | $22M | $16M | $14M | $20M | $12M | $9M | $13M | · | $14M | $13M | $17M | · | $14M | |
| Accrued Liabilities | $77M | $69M | $83M | $62M | $52M | $43M | $55M | $50M | $40M | $40M | · | $33M | $31M | $36M | · | $40M | |
| Current Liabilities | $181M | $199M | $202M | $142M | $131M | $160M | $180M | $110M | $103M | $89M | · | $78M | $66M | $75M | · | $76M | |
| Capital Leases | $102M | $105M | $108M | $111M | $111M | $113M | $113M | $115M | $117M | $119M | · | $122M | $124M | $125M | · | $114M | |
| Other Non-current Liabilities | · | · | · | $2M | $2M | $3M | · | $0 | $0 | $2.0K | · | $408.0K | $625.0K | $837.0K | · | $1M | |
| Total Liabilities | $2.10B | $2.10B | $2.08B | $1.96B | $1.59B | $1.53B | $1.54B | $1.45B | $1.42B | $1.20B | · | $1.18B | $1.11B | $1.12B | · | $1.09B | |
| Long-term Debt | $276M | $292M | $288M | $1.00B | $610M | $610M | $105M | $620M | $629M | $630M | · | · | · | · | · | · | |
| Total Debt | $276M | $292M | · | $176M | $173M | $105M | · | $105M | $104M | $68M | · | $61M | $62M | $64M | · | $64M | |
| Common Stock | $138.0K | $124.0K | $123.0K | $122.0K | $119.0K | $119.0K | $118.0K | $118.0K | $117.0K | $105.0K | · | $94.0K | $94.0K | $94.0K | · | $93.0K | |
| Retained Earnings | $-3.89B | $-3.69B | $-3.49B | $-3.30B | $-3.00B | $-2.86B | $-2.70B | $-2.55B | $-2.39B | $-2.25B | · | $-1.98B | $-1.85B | $-1.72B | · | $-1.45B | |
| AOCI | $-4M | $-2M | $630.0K | $34.0K | $-158.0K | $2M | $2M | $5M | $-1M | $-539.0K | · | $-874.0K | $-1M | $-2M | · | $-6M | |
| Stockholders' Equity | $-173M | $-827M | $-660M | $-521M | $-369M | $-266M | $-135M | $-14M | $109M | $-396M | $-386M | $-439M | $-333M | $-229M | $-108M | $-16M | |
| Liabilities + Equity | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Shares Outstanding | · | · | 122,943,172 | · | · | · | 118,209,139 | · | · | · | · | · | · | · | · | · |
Flusso di cassa
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $6M | $2M | $2M | $2M | $2M | $1M | |
| Stock-based Comp | $36M | $30M | $31M | $31M | $28M | $24M | $26M | $25M | $25M | $22M | $19M | $19M | $19M | $15M | $13M | $13M | |
| Other Non-cash | · | $27M | · | · | · | $4M | · | · | · | $-18M | · | · | · | $-8M | · | · | |
| Operating Cash Flow | $-160M | $-145M | $-143M | $-108M | $-128M | $-132M | $-66M | $-102M | $-99M | $-130M | $-74M | $-96M | $-122M | $-122M | $-98M | $-84M | |
| CapEx | $4M | $6M | $6M | $9M | $4M | $6M | $1M | $701.0K | $2M | $0 | $77.0K | $220.0K | $717.0K | $402.0K | $3M | $6M | |
| Investing Cash Flow | $-507M | $145M | $-71M | $-71M | $53M | $106M | $111M | $-45M | $-652M | $33M | $-81M | $73M | $82M | $165M | $29M | $-292M | |
| Net Debt Issued | · | $-3M | · | · | · | $-3M | · | · | · | $-705.0K | · | · | · | · | · | · | |
| Stock Issued | · | · | · | · | $0 | $0 | · | · | · | $94M | · | · | · | $0 | · | · | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $94M | · | · | · | · | · | · | |
| Financing Cash Flow | $793M | $8M | $111M | $330M | $79M | $5M | $2M | $3M | $821M | $104M | $169M | $54M | $5M | $-7M | $30M | $389M | |
| Net Change in Cash | $125M | $7M | $-103M | $152M | $2M | $-21M | $48M | $-143M | $70M | $7M | $13M | $31M | $-34M | $36M | $-39M | $13M | |
| Free Cash Flow | · | $-151M | · | · | · | $-137M | · | · | · | $-130M | · | · | · | $-123M | · | · |
Redditività
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -626.0% | -948.7% | · | -8613.4% | -167.0% | -9856.3% | · | -30410.6% | -52277.9% | -15118.0% | · | -32345.2% | -14077.2% | -2698.3% | · | -4311.8% | |
| Net Margin | -694.4% | -1064.5% | · | -15815.0% | -201.3% | -10220.1% | · | -34675.0% | -57557.4% | -16244.7% | · | -34238.6% | -14837.0% | -2846.1% | · | -5658.4% | |
| EBITDA Margin | -626.0% | -931.2% | · | -8613.4% | -167.0% | -9710.6% | · | -30410.6% | -52277.9% | -14838.8% | · | -32345.2% | -14077.2% | -2658.2% | · | -4311.8% | |
| ROA | -12.6% | -16.2% | · | -21.3% | -9.8% | -15.6% | · | -14.8% | -12.4% | -16.0% | · | -14.2% | -16.6% | -15.0% | · | -14.9% | |
| ROE | 73.3% | 37.7% | · | 114.5% | 103.3% | 48.7% | · | 70.9% | 127.6% | 43.4% | · | 56.9% | 116.1% | 232.9% | · | -122.1% |
Liquidità e Solvibilità
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.7 | 4.2 | · | 6.9 | 6.8 | 6.0 | · | 9.3 | 10.4 | 7.2 | · | 7.2 | 8.9 | 9.0 | · | 11.6 | |
| Quick Ratio | 1.5 | 0.7 | · | 1.6 | 0.6 | 0.5 | · | 0.4 | 1.9 | 1.4 | · | 1.3 | 1.1 | 1.4 | · | 1.4 | |
| Debt / Equity | -1.6 | -0.4 | · | -0.3 | -0.5 | -0.4 | · | -7.5 | 1.0 | -0.2 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| LT Debt / Equity | -1.4 | -0.3 | · | -0.3 | -0.4 | -0.3 | · | -6.7 | 0.9 | -0.1 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| Interest Coverage | · | · | · | -14.7 | -10.1 | · | · | -15.8 | -10.2 | -17.8 | · | -17.1 | -17.3 | -17.9 | · | -15.9 |
Efficienza
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 1.7 | 4.4 | · | 1.9 | 15.9 | 1.1 | · | 0.3 | 0.5 | 0.9 | · | 0.2 | 0.6 | 1.3 | · | 1.7 |
Per Azione
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $216.71 | $157.01 | · | $16.14 | $558.94 | $13.33 | · | $3.93 | $2.28 | $8.19 | · | $3.93 | $9.05 | $48.47 | · | $26.82 | |
| Cash Flow / Share | · | $-1179.96 | · | · | · | $-1110.73 | · | · | · | $-1270.62 | · | · | · | $-1285.00 | · | · | |
| EPS (TTM) | $-7.23 | $-6.85 | · | $-6.29 | $-5.10 | $-5.29 | · | $-5.38 | $-5.37 | $-5.40 | · | $-5.60 | $-5.77 | $-4.66 | · | $-3.12 |
Valutazione (TTM)
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $68M | $106M | · | $87M | $86M | $19M | · | $3M | $3M | $4M | · | $8M | $10M | $98M | · | $148M | |
| Net Income TTM | $-894M | $-830M | · | $-752M | $-606M | $-615M | · | $-576M | $-545M | $-531M | · | $-527M | $-540M | $-431M | · | $-282M | |
| P/E | -11.8 | -9.6 | · | -8.7 | -6.5 | -7.6 | · | -9.8 | -10.1 | -13.0 | · | -5.3 | -5.7 | -7.6 | · | -15.5 | |
| Earnings Yield | -8.5% | -10.4% | · | -11.4% | -15.4% | -13.2% | · | -10.2% | -9.9% | -7.7% | · | -19.0% | -17.7% | -13.2% | · | -6.4% |
Periodo più recente a sinistra · valori nulli mostrati come ·
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ricavi | $88M | $18M | $8M | $95M | $70M |
| Margine Operativo % | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% |
| Utile netto | $-785M | $-590M | $-526M | $-389M | $-215M |
| EPS Diluito | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 |
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Debito / Patrimonio Netto | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 |
| Rapporto corrente | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 |
| Quick Ratio | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 |
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flusso di cassa libero | $-535M | $-400M | $-416M | $-311M | $-191M |
Proprietari istituzionali (13F) 535 filer · $13.2B totale · Aggiornato al 30 Settembre 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
Detentori
535
Valore detenuto
$13.2B
Nuove posizioni
95
Posizioni chiuse
49
Attività istituzionale — Q2 2026 vs trimestre precedente
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 95 (-11 vs trimestre precedente) | 49 (-7 vs trimestre precedente) | 238 (+49 vs trimestre precedente) | 113 (-29 vs trimestre precedente) | +10.8M |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| BlackRock, Inc. | $1.711.838.738 | 20.094.362 | 12,99% | Azioni |
| VANGUARD GROUP INC | $765.538.243 | 12.048.131 | 5,81% | Azioni |
| WELLINGTON MANAGEMENT GROUP LLP | $590.517.486 | 6.931.770 | 4,48% | Azioni |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $571.778.157 | 6.711.799 | 4,34% | Azioni |
| STATE STREET CORP | $553.243.709 | 6.494.233 | 4,20% | Azioni |
| VANGUARD CAPITAL MANAGEMENT LLC | $521.151.103 | 6.117.515 | 3,95% | Azioni |
| FMR LLC | $428.657.534 | 5.031.782 | 3,25% | Azioni |
| Avoro Capital Advisors LLC | $425.949.915 | 4.999.999 | 3,23% | Azioni |
| BANK OF AMERICA CORP /DE/ | $394.916.049 | 4.635.709 | 3,00% | Azioni |
| GEODE CAPITAL MANAGEMENT, LLC | $316.325.896 | 3.712.501 | 2,40% | Azioni |
| RTW INVESTMENTS, LP | $243.814.036 | 2.862.003 | 1,85% | Azioni |
| Polar Capital Holdings Plc | $191.988.358 | 2.253.649 | 1,46% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $161.060.214 | 1.890.600 | 1,22% | Opzione Call |
| GOLDMAN SACHS GROUP INC | $150.069.725 | 1.761.588 | 1,14% | Azioni |
| Capital Research Global Investors | $143.683.584 | 1.686.625 | 1,09% | Azioni |
| NORTHERN TRUST CORP | $140.337.319 | 1.647.345 | 1,06% | Azioni |
| JPMORGAN CHASE & CO | $139.150.046 | 1.588.895 | 1,06% | Azioni |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $136.597.224 | 1.603.442 | 1,04% | Azioni |
| Integral Health Asset Management, LLC | $136.304.000 | 1.600.000 | 1,03% | Azioni |
| Point72 Asset Management, L.P. | $135.257.185 | 1.587.712 | 1,03% | Azioni |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $133.388.883 | 1.565.781 | 1,01% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $131.998.327 | 1.549.458 | 1,00% | Azioni |
| ARMISTICE CAPITAL, LLC | $130.340.700 | 1.530.000 | 0,99% | Opzione Call |
| MORGAN STANLEY | $128.664.004 | 1.510.318 | 0,98% | Azioni |
| PRINCIPAL FINANCIAL GROUP INC | $111.740.656 | 1.311.664 | 0,85% | Azioni |
| Capital International Investors | $111.245.191 | 1.305.848 | 0,84% | Azioni |
| Invesco Ltd. | $105.237.167 | 1.235.323 | 0,80% | Azioni |
| ARMISTICE CAPITAL, LLC | $102.342.325 | 1.201.342 | 0,78% | Azioni |
| UBS Group AG | $99.781.940 | 1.171.287 | 0,76% | Azioni |
| Pictet Asset Management Holding SA | $99.038.455 | 1.160.463 | 0,75% | Azioni |
| Frazier Life Sciences Management, L.P. | $98.810.092 | 1.159.879 | 0,75% | Azioni |
| Bank of New York Mellon Corp | $98.027.901 | 1.150.697 | 0,74% | Azioni |
| Holocene Advisors, LP | $97.506.685 | 1.144.579 | 0,74% | Azioni |
| Woodline Partners LP | $93.769.315 | 1.100.708 | 0,71% | Azioni |
| D. E. Shaw & Co., Inc. | $89.287.894 | 1.048.103 | 0,68% | Azioni |
| NORGES BANK | $86.512.319 | 1.015.522 | 0,66% | Azioni |
| Royalty Pharma Sub-Manager, LLC | $83.519.594 | 980.392 | 0,63% | Azioni |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $81.937.000 | 961.815 | 0,62% | Azioni |
| VANGUARD FIDUCIARY TRUST CO | $77.218.175 | 906.423 | 0,59% | Azioni |
| CITADEL ADVISORS LLC | $77.062.874 | 904.600 | 0,58% | Opzione Call |
| FRANKLIN RESOURCES INC | $75.911.721 | 891.087 | 0,58% | Azioni |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $70.521.134 | 827.810 | 0,53% | Azioni |
| Melqart Asset Management (UK) Ltd | $65.385.455 | 767.525 | 0,50% | Azioni |
| Siren, L.L.C. | $64.655.121 | 758.952 | 0,49% | Azioni |
| Fisher Asset Management, LLC | $63.355.547 | 743.697 | 0,48% | Azioni |
| Foresite Capital Management IV, LLC | $60.884.867 | 714.695 | 0,46% | Azioni |
| Balyasny Asset Management L.P. | $60.599.821 | 711.349 | 0,46% | Azioni |
| Deep Track Capital, LP | $59.633.000 | 700.000 | 0,45% | Azioni |
| JANE STREET GROUP, LLC | $59.633.000 | 700.000 | 0,45% | Opzione Call |
| BNP PARIBAS FINANCIAL MARKETS | $58.702.470 | 689.077 | 0,45% | Azioni |
Insider aziendali 52 insider · 19 dirigenti · 23 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Robert I Blum | President & CEO | 28 Settembre 2026 M | 278.544 | 0 | 20 | $-17.291.957 |
| Sung Lee | EVP, Chief Financial Officer | 01 Luglio 2026 M | 63.221 | 0 | 5 | $-5.695.855 |
| Ching Jaw | SVP Finance & CFO | 06 Marzo 2023 A | 87.346 | 0 | 0 | $0 |
| Sharon Surrey Barbari | EVP, Finance & CFO | 28 Febbraio 2017 F | 40.323 | 0 | 0 | $0 |
| Fady Ibraham Malik | EVP Research & Development | 22 Settembre 2026 M | 153.902 | 0 | 21 | $-4.654.735 |
| Andrew Callos | EVP, Chief Commercial Officer | 31 Agosto 2026 M | 58.555 | 0 | 25 | $-16.021.293 |
| Jeffrey Hessekiel | Chief Legal & Admin Officer | 15 Marzo 2026 A | 107.943 | 0 | 0 | $0 |
| Robert Wong | VP, Chief Accounting Officer | 03 Dicembre 2024 A | 18.655 | 0 | 0 | $0 |
| Brett A Pletcher | EVP, Chief Legal Officer | 30 Agosto 2024 A | 33.140 | 0 | 0 | $0 |
| Mark A Schlossberg | SVP - Legal & General Counsel | 15 Marzo 2022 M | 103.408 | 0 | 0 | $0 |
| David Cragg | Chief HR & Admin Officer | 07 Marzo 2022 F | 153.233 | 0 | 0 | $0 |
| Caryn Gordon Mcdowell | GC & Chief Compliance Officer | 27 Febbraio 2018 A | 32.548 | 0 | 0 | $0 |
| Peter S Roddy | SVP Finance & CAO | 27 Febbraio 2018 A | 21.520 | 0 | 0 | $0 |
| Bradley Paul Morgan | SVP Drug Discovery & Early Dev | 31 Agosto 2017 M | 46.441 | 0 | 0 | $0 |
| Bonnie Charpentier | SVP Regulatory & Compliance | 28 Febbraio 2017 A | 29.004 | 0 | 0 | $0 |
| Andrew A Wolff | SVP & CMO | 28 Febbraio 2017 A | 47.255 | 0 | 0 | $0 |
| David J Morgans JR | EVP-Preclinical R&D | 28 Febbraio 2011 A | 42.000 | 0 | 0 | $0 |
| Michael Rabson | SVP Business Dev/Legal & GC | 18 Dicembre 2009 M | 20.043 | 0 | 0 | $0 |
| Jay K Trautman | VP, Discovery Research | 29 Febbraio 2008 A | 47.896 | 0 | 0 | $0 |
| Robert E Landry | Direttore | 15 Settembre 2026 S | 8.184 | 0 | 2 | $-146.790 |
| Lynne B Parshall | Direttore | 01 Settembre 2026 S | 10.784 | 0 | 4 | $-1.357.500 |
| Robert Arthur Harrington | Direttore | 15 Luglio 2026 A | 21.932 | 0 | 1 | $-143.620 |
| James M Daly | Direttore | 15 Luglio 2026 A | 3.390 | 0 | 0 | $0 |
| Edward M. Kaye MD | Direttore | 15 Luglio 2026 A | 10.434 | 0 | 4 | $-2.837.811 |
| Nancy Wysenski | Direttore | 15 Luglio 2026 A | 33.992 | 0 | 0 | $0 |
| Wendell Wierenga | Direttore | 15 Luglio 2026 A | 35.563 | 0 | 3 | $-1.881.925 |
| John T Henderson | Direttore | 15 Luglio 2026 A | 78.360 | 0 | 2 | $-2.078.525 |
| Muna Bhanji | Direttore | 27 Maggio 2026 A | 26.361 | 0 | 0 | $0 |
| Wendall Wierenga | Direttore | 15 Luglio 2025 A | 32.345 | 0 | 0 | $0 |
| COSTA SANTO J | Direttore | 15 Maggio 2024 A | 20.600 | 0 | 0 | $0 |
| Sandford D Smith | Direttore | 02 Gennaio 2024 A | 18.801 | 0 | 0 | $0 |
| Robert Califf | Direttore | 03 Gennaio 2022 A | 6.003 | 0 | 0 | $0 |
| GAGE L PATRICK | Direttore | 08 Novembre 2021 M | 28.932 | 0 | 0 | $0 |
| Denise Gilbert | Direttore | 20 Maggio 2015 J | · | 0 | 0 | $0 |
| Stephen M Dow | Direttore | 02 Gennaio 2013 A | 1.421.052 | 0 | 0 | $0 |
| James A Spudich | Direttore | 18 Maggio 2011 A | 180.600 | 0 | 0 | $0 |
| Grant A Heidrich III | Direttore | 03 Gennaio 2011 A | 93.755 | 0 | 0 | $0 |
| Michael Schmertzler | Direttore | 03 Giugno 2010 S | 4.340.923 | 0 | 0 | $0 |
| Mark Mcdade | Direttore | 21 Maggio 2009 A | · | 0 | 0 | $0 |
| Charles J Homcy | Direttore | 22 Maggio 2008 A | · | 0 | 0 | $0 |
| William J Rutter | Direttore | 29 Aprile 2004 C | 172.413 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VI LP | Proprietario del 10% | 29 Aprile 2004 C | 1.615.716 | 0 | 0 | $0 |
| SRB ASSOCIATES VIII LP | Proprietario del 10% | 29 Aprile 2004 C | 771.052 | 0 | 0 | $0 |
| SRB ASSOCIATES VII LP | Proprietario del 10% | 29 Aprile 2004 C | 650.000 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VIII LP | Proprietario del 10% | 29 Aprile 2004 C | 755.631 | 0 | 0 | $0 |
| Elisabeth Schnieders | · | 28 Febbraio 2017 A | 43.919 | 0 | 0 | $0 |
| James H Sabry | · | 03 Giugno 2010 M | 0 | 0 | 0 | $0 |
| SEVIN ROSEN VII AFFILIATES FUND LP | · | 29 Aprile 2004 C | 24.050 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VII LP | · | 29 Aprile 2004 C | 625.950 | 0 | 0 | $0 |
| SRB ASSOCIATES VI LP | · | 29 Aprile 2004 C | 1.742.951 | 0 | 0 | $0 |
| SEVIN ROSEN VIII AFFILIATES FUND LP | · | 29 Aprile 2004 C | 15.421 | 0 | 0 | $0 |
| SEVIN ROSEN VI AFFILIATES FUND LP | · | 29 Aprile 2004 C | 127.235 | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Proprietà ETF Posseduti da 56 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| PTH · Invesco Exchange-Traded Fund Trust | 1,54% | 85.826 SH | 01 Ottobre 2026 | Giornaliero |
| BBP · ETFis Series Trust I | 1,51% | 19.346 NS | 31 Luglio 2026 | N-PORT |
| XMMO · Invesco Exchange-Traded Fund Trust | 0,83% | 881.672 SH | 01 Ottobre 2026 | Giornaliero |
| LABU · Direxion Shares ETF Trust | 0,79% | 50.312 NS | 31 Luglio 2026 | N-PORT |
| IBB · iShares Trust | 0,73% | 1.020.305 SH | 11 Settembre 2026 | Giornaliero |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,72% | 53.872 NS | 31 Luglio 2026 | N-PORT |
| NUSC · Nushares ETF Trust | 0,64% | 107.023 NS | 31 Luglio 2026 | N-PORT |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,64% | 102.933 SH | 19 Agosto 2026 | Giornaliero |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,60% | 9.831 SH | 01 Ottobre 2026 | Giornaliero |
| IQSM · New York Life Investments ETF Trust | 0,35% | 14.748 NS | 31 Luglio 2026 | N-PORT |
| DWAS · Invesco Exchange-Traded Fund Trust … | 0,34% | 21.280 SH | 01 Ottobre 2026 | Giornaliero |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,34% | 761.130 SH | 19 Agosto 2026 | Giornaliero |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,33% | 72.343 SH | 19 Agosto 2026 | Giornaliero |
| RSSL · Global X Funds | 0,33% | 63.327 NS | 31 Luglio 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,32% | 1.797.986 SH | 19 Agosto 2026 | Giornaliero |
| IVOO · VANGUARD ADMIRAL FUNDS | 0,32% | 219.413 SH | 19 Agosto 2026 | Giornaliero |
| IWM · iShares Trust | 0,32% | 3.378.753 SH | 11 Settembre 2026 | Giornaliero |
| IVOV · VANGUARD ADMIRAL FUNDS | 0,31% | 53.623 SH | 19 Agosto 2026 | Giornaliero |
| ISCG · iShares Trust | 0,30% | 39.366 SH | 11 Settembre 2026 | Giornaliero |
| PTMC · Pacer Funds Trust | 0,29% | 14.892 NS | 31 Luglio 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,27% | 48.364 NS | 31 Luglio 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0,24% | 20.179 NS | 31 Luglio 2026 | N-PORT |
| ESML · iShares Trust | 0,23% | 88.671 SH | 11 Settembre 2026 | Giornaliero |
| MIDU · Direxion Shares ETF Trust | 0,22% | 1.994 NS | 31 Luglio 2026 | N-PORT |
| PWS · Pacer Funds Trust | 0,22% | 687 NS | 31 Luglio 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,22% | 16.176 NS | 31 Luglio 2026 | N-PORT |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,21% | 54.306 NS | 31 Luglio 2026 | N-PORT |
| FFLG · FIDELITY COVINGTON TRUST | 0,20% | 15.469 NS | 31 Luglio 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,19% | 3.254 NS | 31 Luglio 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,17% | 40.586 SH | 19 Agosto 2026 | Giornaliero |
| VB · VANGUARD INDEX FUNDS | 0,14% | 3.113.794 SH | 19 Agosto 2026 | Giornaliero |
| VHT · VANGUARD WORLD FUND | 0,14% | 333.056 SH | 19 Agosto 2026 | Giornaliero |
| VXF · VANGUARD INDEX FUNDS | 0,13% | 1.557.779 SH | 19 Agosto 2026 | Giornaliero |
| FHLC · FIDELITY COVINGTON TRUST | 0,12% | 52.671 NS | 31 Luglio 2026 | N-PORT |
| ESSC · Strategy Shares | 0,10% | 466 NS | 31 Luglio 2026 | N-PORT |
| WSML · iShares Trust | 0,09% | 7.841 SH | 11 Settembre 2026 | Giornaliero |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,07% | 15.233 SH | 19 Agosto 2026 | Giornaliero |
| IWO · iShares Trust | 0,07% | 133.196 SH | 11 Settembre 2026 | Giornaliero |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,07% | 27.790 SH | 01 Ottobre 2026 | Giornaliero |
| TILT · FlexShares Trust | 0,02% | 5.740 NS | 31 Luglio 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,02% | 4.315.260 SH | 19 Agosto 2026 | Giornaliero |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,02% | 10.880 SH | 19 Agosto 2026 | Giornaliero |
| ESGV · VANGUARD WORLD FUND | 0,02% | 29.174 SH | 19 Agosto 2026 | Giornaliero |
| IUSG · iShares Trust | 0,01% | 64.511 SH | 11 Settembre 2026 | Giornaliero |
| IUSV · iShares Trust | 0,01% | 53.197 SH | 11 Settembre 2026 | Giornaliero |
| ITOT · iShares Trust | 0,01% | 180.021 SH | 11 Settembre 2026 | Giornaliero |
| IWV · iShares Trust | 0,01% | 36.083 SH | 10 Settembre 2026 | Giornaliero |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 106.638 SH | 19 Agosto 2026 | Giornaliero |
| RWK · Invesco Exchange-Traded Fund Trust … | 0,00% | 478 SH | 29 Settembre 2026 | Giornaliero |
| IJH · iShares Trust | · | 4.763.860 SH | 11 Settembre 2026 | Giornaliero |
| IJK · iShares Trust | · | 425.186 SH | 11 Settembre 2026 | Giornaliero |
| IJJ · iShares Trust | · | 318.457 SH | 21 Agosto 2026 | Giornaliero |
| IWN · iShares Trust | · | 1.107.696 SH | 11 Settembre 2026 | Giornaliero |
| XJH · iShares Trust | · | 18.548 SH | 08 Settembre 2026 | Giornaliero |
| ISCB · iShares Trust | · | 5.565 SH | 11 Settembre 2026 | Giornaliero |
| SMLF · iShares Trust | · | 71.881 SH | 11 Settembre 2026 | Giornaliero |
CYTK Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
rating · 28 analisti
COMPRA
Target mediano
$107.50
+63,9%
6 21,4%
Acquisto forte
19 67,9%
Compra
3 10,7%
Mantieni
0 0,0%
Vendi
0 0,0%
Vendita forte
Target Price a 12 Mesi
20 analisti · 2026-09-29Target medio $109.90 +67,5%
← Sotto tutti i target
Prezzo attuale $65.60
Basso$85.00
Media$109.90
Alto$146.00
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
Base FY, prezzi alla chiusura dell'ultimo anno fiscale di ciascuna società.
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | · |
| KRYS | $7.20B | 36.0 | 33.9% | 52.6% | 18.1% | · |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | · |
| KYMR | $6.33B | -21.1 | -16.7% | -794.0% | -24.4% | · |
| PTGX | $5.47B | -42.6 | -89.4% | -282.8% | -20.3% | · |
| PCVX | $6.05B | -8.2 | · | · | -26.6% | · |
| TGTX | $4.63B | 10.8 | 87.3% | 72.6% | 96.7% | · |
| SYRE | $2.56B | 10.1 | -62.0% | · | -26.5% | · |
| PRAX | $7.43B | -21.9 | 249.5% | · | -47.3% | · |
Ultime notizie Notizie recenti che menzionano questa società
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
Scegli le metriche che contano per te: fai clic sul + accanto a qualsiasi riga in Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Fonte: SEC 10-Q depositato Ago 6, 2026